Kura Oncology reports Q3 2026 results with 53% rise in KOMZIFTI revenue and secures up to $300M financing
Kura Oncology announced third‑quarter 2026 net product revenue of $13.9 million for its newly launched drug KOMZIFTI, a 53% sequential increase. Net loss narrowed to $70.2 million and cash balances stood at $492.1 million. The company disclosed a financing agreement with Oberland Capital that could provide up to $300 million, of which $55 million has been received, and outlined a planned ~40‑patient registrational study of darlifarnib in the first half of 2027.
Why it matters
The financing arrangement gives Kura additional runway to fund commercial expansion and pipeline development, while the strong product revenue and cash position improve its short‑term liquidity despite a continued net loss (the company said the cash will support the operating plan beyond the 2028 trial readout).
Key facts
- 1KOMZIFTI net product revenue was $13.9 million, up 53% sequentially from the prior quarter. fool.com
- 2Net loss for the quarter was $70.2 million, a 5% decrease year‑over‑year. fool.com
- 3Cash and equivalents totaled $492.1 million as of September 30, 2026. fool.com
- 4Oberland Capital financing agreement provides up to $300 million, with $55 million received at closing ($50 million debt tranche and $5 million equity investment). fool.com
- 5New patient starts for KOMZIFTI were 150, a 30% increase sequentially. fool.com
- 6The company plans a registrational study of darlifarnib enrolling approximately 40 patients in the first half of 2027. seekingalpha.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.